You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一图看懂金斯瑞生物科技(1548.HK)2019年中期业绩
格隆汇 09-11 12:33

关于金斯瑞生物科技股份有限公司

金斯瑞生物科技股份有限公司(股票代码HK01548)是全球化的生物科技集团公司。集团植根于领先的基因合成技术,业务范围涵盖生命科学服务及产品、工业合成生物产品、生物药CDMO及细胞治疗四大领域。

金斯瑞成立于2002年,并于2015年在港交所主板挂牌上市。(集团总部位于中国南京,)运营实体遍布大中华区、北美区、欧洲区及亚太区,并以此为依托,为全球160多个国家和地区的30多万客户提供优质、便捷、可靠的服务与产品。

目前,金斯瑞在全球拥有超过2900名员工,其中34%以上的员工拥有硕士或博士学位。金斯瑞拥有多项知识产权及技术机密,其中包含100多项授权专利及270多项专利申请。截至2019年6月30日,有超过40,300篇经国际同业审阅的学术期刊文献引述了金斯瑞的服务及产品。

秉承“用生物技术使人和自然更健康”的企业使命,金斯瑞将一如既往地致力于成为最受信赖的生物科技公司。

更多信息,请访问金斯瑞官网 https://www.genscript.com.cn

下面让我们以一图来全方位了解金斯瑞生物科技2019年中期业绩吧。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account